Height and weight adjusted dose versus fixed dose of hyperbaric bupivacaine for spinal anaesthesia in cesarean section to prevent maternal hypotension

Height weight adjusted dose versus fixed dose of hyperbaric bupivacaine in elective cesarean section to prevent maternal hypotension A prospective, double blinded, Randomized Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/096998

Enrollment

Registered

2025-11-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O82- Encounter for cesarean delivery without indication

Interventions

Intervention1: Group HW: In this, patients will receive 0.5% hyperbaric Bupivacaine intrathecally, with the dosage according to their height and weight using Harten’s dosing chart Dose - According to

60(4):348-53. doi: 10.1111/j.1365-2044.2005.04113.x. PMID: 15766337. Frequency - at the time of Induction Duration of intervention - Subarachnoid block given before the onset of surgery Route of adm

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant woman classified as ASA 2 Pregnant woman carrying singleton pregnancy (more than 37weeks of gestation) Pregnant woman with weight 50-110kg and height of 140-180cm Patients who is scheduled for elective cesarean section

Exclusion criteria

Exclusion criteria: Pregnant belonged to ASA III or IV Patients having pre eclampsia and cardiac or respiratory diseases, gestational and pre diabetes Patient having IUGR, Fetal anomalies Patient having abruptio placenta, placenta previa,accreta, percreta Patients requiring emergency LSCS Patient declining participation

Design outcomes

Primary

Measure	Time frame
To study the incidence of maternal hypotension in height - weight adjusted dose regimen group versus fixed dose groupTimepoint: To note intraoperative vitals at 0,2,4,6,8,10,15,30,45,60 minutes	—

Secondary

Measure	Time frame
To assess the time taken to achieve sensory level upto T6 level in both the groups To assess the time taken to attain motor block according to Modified Bromage scale in both the groups To assess dose of mephentermine used in both the groups To assess the incidence of complications like hypotension, bradycardia, shivering, nausea, and vomiting in both the groups To assess neonatal APGAR score at 1 and 5 mins in both the groupsTimepoint: To note intraoperative vitals at 0,2,4,6,8,10,15,30,45,60 minutes	—

Measure

Time frame

To assess the time taken to achieve sensory level upto T6 level in both the groups To assess the time taken to attain motor block according to Modified Bromage scale in both the groups To assess dose of mephentermine used in both the groups To assess the incidence of complications like hypotension, bradycardia, shivering, nausea, and vomiting in both the groups To assess neonatal APGAR score at 1 and 5 mins in both the groupsTimepoint: To note intraoperative vitals at 0,2,4,6,8,10,15,30,45,60 minutes

—

Countries

India

Contacts

Public ContactDr Jyoti Petkar

RajaRajeswari Medical College and Hospital

jokiran2009@gmail.com7726899533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026